SBIR Phase II: Rapid disinfection using compact plasma reactors

SBIR 第二阶段：使用紧凑型等离子体反应器快速消毒

• 批准号: 2151628
• 负责人: Justin Kosky
• 金额: $ 87.83万
• 依托单位: SurfPlasma, Inc.
• 依托单位国家: 美国
• 项目类别: Cooperative Agreement
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-10-01 至 2025-09-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2151628&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Rapid; disinfection

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project addresses the societal need for a non-thermal, economical, and efficient solution for sterilizing deadly pathogens that are common in medical facilities and everyday living spaces. The commercial opportunity lies in developing a non-thermal, portable, safe, and economical sterilization device for materials contaminated with virus, bacteria, and fungi. The proposed technology will be used in areas that are lacking in current state-of-the-art sterilization technologies. It operates at low temperature, necessary for temperature-sensitive equipment, is ecofriendly, has high throughput, requires little maintenance, and includes an inbuilt mixing system for the sterilization of complex surface geometries. Applications include sterilizing personal protective equipment (PPE), surgical tools, medical devices, food, beverages, etc. from harmful pathogens. The addressable market consists of healthcare facilities, medical device companies, and food and beverage companies. The major impact will be in crowded facilities and community settings where rapid disinfection of objects is required. Additionally, the technology can be integrated with existing systems like refrigeration units. The technology is expected to save lives by preventing hospital-acquired infections, the further spread of COVID-19, and possible future outbreaks.This SBIR Phase II project proposes a sterilization device that operate at low temperatures, works with complex geometries, and is low energy and low cost. These areas are not currently addressed by one single, state-of-the-art sterilization technology. The solution is based on an active plasma module (APM). Previously, research established APM efficacy against SARS CoV-2 and its surrogate on metal, plastic, and fabric, and the required operating conditions (exposure times, ozone requirements, and power) to achieve sterilization. The objectives in this project include prototype development with (i) efficacy tests against BioSafety Level (BSL)-2 and -3 pathogens, (ii) cycle times, ozone requirements, and power demands, (iii) a practical ozone removal system to meet safety limits, (iv) material compatibility data, and (v) a user-friendly control interface. The team will also examine APM quality control, the ability to meet required product specifications, and management of the reverse-engineering threat. Successful Phase II completion will result in a market-ready prototype with sterilization data against various pathogens and product specifications required for customer adoption. The project will advance research on power efficient ozone sterilization.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）II期项目的更广泛的影响/商业潜力解决了社会对在医疗机构和日常生活空间中常见的致命病原体的非热，经济和有效解决方案的社会需求。商业机会在于开发一种非热，便携式，安全和经济的灭菌装置，用于被病毒，细菌和真菌污染的材料。拟议的技术将用于当前最新灭菌技术缺乏的领域。它在低温下运行，对温度敏感的设备必不可少，它具有环境友好，具有很高的吞吐量，几乎不需要维护，并且包括一个内置的混合系统，用于对复杂表面几何形状进行灭菌。应用程序包括对个人防护设备（PPE），手术工具，医疗设备，食物，饮料等进行的，有害病原体。可寻址的市场包括医疗机构，医疗设备公司以及食品和饮料公司。主要影响将是在需要快速消毒物体的拥挤设施和社区环境中。此外，该技术可以与冷藏单元等现有系统集成。预计该技术将通过防止医院获得的感染，COVID-19的进一步传播以及可能的未来爆发来挽救生命。该SBIR II期项目提出了一种在低温下运行的灭菌装置，具有复杂的几何形状，并且能量低和低成本。这些区域目前尚未通过一种最先进的灭菌技术来解决。该解决方案基于活动等离子体模块（APM）。以前，研究确立了针对SARS COV-2及其在金属，塑料和织物上的APM功效，以及所需的工作条件（暴露时间，臭氧需求和功率）以实现灭菌。该项目的目标包括针对生物安全水平（BSL）-2和-3病原体的功效测试的原型开发，（II）周期时间，臭氧需求和功率需求，（iii）实用的臭氧拆卸系统，可满足安全限制，（iv）安全性数据，（v）用户效率界面的材料兼容数据，（iv）。 该团队还将检查APM质量控制，满足所需产品规格的能力以及对反向工程威胁的管理。 成功的II阶段完成将导致提供市场准备就绪的原型，并具有灭菌数据，以与客户采用所需的各种病原体和产品规格。该项目将推进对电力臭氧灭菌的研究。该奖项反映了NSF的法定任务，并被认为是值得通过基金会的知识分子优点和更广泛影响的评论标准来评估值得支持的。